Home532523 • BOM
add
Biocon Ltd
Nakaraang pagsara
₹390.35
Sakop ng araw
₹390.30 - ₹396.85
Sakop ng taon
₹290.80 - ₹424.95
Market cap
474.09B INR
Average na Volume
121.51K
P/E ratio
81.58
Dividend yield
0.13%
Primary exchange
NSE
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (INR) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 41.73B | 9.20% |
Gastos sa pagpapatakbo | 25.16B | 17.78% |
Net na kita | 1.44B | 472.91% |
Net profit margin | 3.45 | 422.73% |
Kita sa bawat share | 2.74 | 1,986.89% |
EBITDA | 7.13B | 0.91% |
Aktuwal na % ng binabayarang buwis | 23.60% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (INR) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 61.04B | 130.29% |
Kabuuang asset | — | — |
Kabuuang sagutin | — | — |
Kabuuang equity | 330.55B | — |
Natitirang share | 1.33B | — |
Presyo para makapag-book | 1.88 | — |
Return on assets | — | — |
Return on capital | 1.60% | — |
Cash Flow
Net change in cash
| (INR) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 1.44B | 472.91% |
Cash mula sa mga operasyon | — | — |
Cash mula sa pag-invest | — | — |
Cash mula sa financing | — | — |
Net change in cash | — | — |
Malayang cash flow | — | — |
Tungkol
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. The company was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy, and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA.
Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
Itinatag
Nob 29, 1978
Headquarters
Website
Mga Empleyado
16,420